RECCE® 327
Broad‑spectrum bacterial infections (including ABSSSI, diabetic foot, burn wounds, HAP/VAP)
Phase 3Active
Key Facts
Indication
Broad‑spectrum bacterial infections (including ABSSSI, diabetic foot, burn wounds, HAP/VAP)
Phase
Phase 3
Status
Active
Company
About Recce Pharmaceuticals
Recce creates synthetic polymer anti‑infectives to combat multidrug‑resistant bacteria and viruses.
View full company profile